That would make Tweed's cap significantly lower than its projected revenue. Most speculative MJ stocks trade notably higher than their projected revenue, yet you somehow think underpricing the one public company with a license, a growing list of patients and ongoing revenue streams is reasonable. Can you please explain why you think that? I would say the fact their patient demand is already "multiple times higher" than expected, thus their need to buy additional MJ from other suppliers, sufficiently proves that the business plan/brand works.
News 
Market Data 
Discover 
